Skip to content
Bored Studies
RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

Kodiak Sciences Inc · NCT07734844

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
910
US sites recruiting
9
Study start
August 3, 2026
Record last updated
August 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO

Being studied: Tabirafusp tedromer; Aflibercept (2.0 mg)

Conditions: Diabetic Macular Edema (DME)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • DME, treatment-naïve or previously-treated
  • Male or female ≥18 years of age with Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%
  • Capable of giving informed signed consent

Exclusion Criteria

  • Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.
  • Current or history of retinal detachment (tractional or rhegmatogenous) in the Study Eye

Recruiting US locations

Study contacts (from the official record)

  • Kodiak Sciences Inc · 6502810850 · ClinicalTrials@kodiak.com
All diabetes studies in California →
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer… (NCT07734844) | Bored Studies